Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study - SENSOR

ederlands Kanker Instituut0 个研究点目标入组 61 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

Trial is onging in other countries

•1. Patients with locally advanced (incurable) or metastatic colorectal cancer or NSCLC that have only one line standard of care treatment left, or will start with a study treatment. Patients should have received a first line standard of care treatment.
•2. No treatment options with curative intent
•3. RECIST 1.1 measurable/evaluable disease
•4. Safe biopsy of a metastatic lesion possible
•5. Adequate organ function
•6. WHO performance status 0-1
•7. Age > 18 years and written informed consent;In- and exclusion criteria for each drug are further determined by individual drug characteristics that are provided by pharmaceutical partners.

•1. Pregnant or lactating (nursing) women
•2. Prior malignancy within 5 years.
•3. Known infection with human immunodeficiency virus (HIV)
•4. Leptomeningeal carcinomatosis
•5. Symptomatic brain metastasis.
•6. Other psychiatric or medical conditions that would make the patient unfit for participation.
•7. Life expectancy of less than 3 months from tumor progression under standard of care. ;In- and exclusion criteria for each drug are further determined by individual drug characteristics that are provided by pharmaceutical partners.

发起方

ederlands Kanker Instituut